This press conference, “Late-breaking Clinical Trials,” held on Saturday, March 31 was hosted José Baselga, M.D., Ph.D., associate director and chief of hematology/oncology at the Massachusetts General Hospital Cancer Center in Boston, Mass., and discusses the following research:
- Early Clinical Data Show Galeterone Safe, Effective Against Prostate Cancer
- Metformin Appeared to Slow Prostate Cancer Growth
- Biomarker Identified in Relation to Drug Response in Refractory Urothelial Cancer
- Combination Targeted Therapy Well Tolerated, Effective for Refractory Ewing’s Sarcoma Tumors
- Selumetinib Controlled Recurrent Low-grade Serous Ovarian Cancer
- Oral Vitamin D Supplements Reduced Levels of Ki67 in Prostate Cancer Cells
Listen to a recording of the teleconference:
Download* the mp3 of the teleconference (63.55 MB, 1 hour, 9 minutes and 24 seconds)
*On a PC, right mouse click on the "Download" link and select "Save link as..." in Firefox or "Save Target as..." in Internet Explorer.